METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail of immune drugs shows promise against tough prostate cancer
Disease control CompletedThis study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received different combinations of a vaccine and other immune-boosting drugs. The goal was to see if these combina…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New oral therapy cycle shows promise for tough prostate cancer
Disease control CompletedThis study tested a new way to treat men with advanced prostate cancer that no longer responds to standard hormone therapy. Fifteen men took high-dose oral testosterone for one week, then no treatment for one week, repeating for three months. If the cancer worsened, they switched…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug MK-5684 tested for safety in chinese men with advanced prostate cancer
Disease control CompletedThis early-phase study tested the safety and how the body processes the drug MK-5684 in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goal was to check for side effects and measure drug levels in the blood. Th…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
New hope for Hard-to-Treat prostate cancer in japanese men
Disease control CompletedThis early-stage study tested the safety of a new drug called opevesostat (MK-5684) in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy and chemotherapy. The goal was to see if the drug is safe and how it works in the body…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
Immune priming therapy shows promise in tough prostate cancer
Disease control CompletedThis early-phase study tested a new cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The treatment aims to boost the body's natural killer cells to fight the cancer. Researchers looked for the safest and most effectiv…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New drug combo shows promise for tough prostate cancer
Disease control CompletedThis study tested a new drug called vudalimab, alone or with standard treatments, in 72 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the drug is safe and can shrink tumors or lower PSA levels. Participants had to have cancer…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
Prostate cancer patients pick their poison: cabazitaxel or docetaxel?
Symptom relief CompletedThis study asked men with advanced prostate cancer which of two standard chemotherapies they preferred based on side effects. 195 patients tried both drugs in sequence and then stated their preference. The goal was to understand which treatment is better tolerated, helping doctor…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated May 26, 2026 03:06 UTC
-
New PET scan method could improve prostate cancer treatment monitoring
Knowledge-focused CompletedThis study tested whether a special PET scan (18F-fluciclovine) can better show how prostate cancer responds to common treatments like abiraterone, enzalutamide, or docetaxel. Nine men with advanced prostate cancer that no longer responds to hormone therapy received one of these …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC
-
Prostate cancer drug Radium-223 under safety microscope in 1,472-Patient study
Knowledge-focused CompletedThis study looked at the long-term safety of Radium-223 in 1,472 men with metastatic castration-resistant prostate cancer. Researchers tracked side effects, bone marrow problems, and the risk of developing new cancers after treatment. The goal was to understand the drug's safety …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 18, 2026 12:01 UTC